Compare Panacea Biotech with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs CADILA HEALTHCARE - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH CADILA HEALTHCARE PANACEA BIOTECH/
CADILA HEALTHCARE
 
P/E (TTM) x 15.4 30.6 50.4% View Chart
P/BV x 6.0 5.4 112.0% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PANACEA BIOTECH   CADILA HEALTHCARE
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
CADILA HEALTHCARE
Mar-20
PANACEA BIOTECH/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs354352 100.4%   
Low Rs138207 66.9%   
Sales per share (Unadj.) Rs74.6139.2 53.6%  
Earnings per share (Unadj.) Rs6.711.8 56.8%  
Cash flow per share (Unadj.) Rs15.518.6 83.5%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs57.2101.4 56.4%  
Shares outstanding (eoy) m61.251,023.74 6.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.32.0 164.3%   
Avg P/E ratio x36.823.7 155.0%  
P/CF ratio (eoy) x15.915.0 105.5%  
Price / Book Value ratio x4.32.8 155.9%  
Dividend payout %029.8 0.0%   
Avg Mkt Cap Rs m15,061286,033 5.3%   
No. of employees `0002.313.4 17.3%   
Total wages/salary Rs m1,47124,145 6.1%   
Avg. sales/employee Rs Th1,973.610,632.7 18.6%   
Avg. wages/employee Rs Th635.61,801.2 35.3%   
Avg. net profit/employee Rs Th176.8898.5 19.7%   
INCOME DATA
Net Sales Rs m4,567142,531 3.2%  
Other income Rs m451,139 3.9%   
Total revenues Rs m4,612143,670 3.2%   
Gross profit Rs m2,03024,198 8.4%  
Depreciation Rs m5406,965 7.8%   
Interest Rs m1,0483,418 30.7%   
Profit before tax Rs m48614,954 3.3%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m773,198 2.4%   
Profit after tax Rs m40912,044 3.4%  
Gross profit margin %44.417.0 261.8%  
Effective tax rate %15.921.4 74.2%   
Net profit margin %9.08.5 106.0%  
BALANCE SHEET DATA
Current assets Rs m2,41587,154 2.8%   
Current liabilities Rs m9,07782,694 11.0%   
Net working cap to sales %-145.93.1 -4,662.4%  
Current ratio x0.31.1 25.2%  
Inventory Days Days6571 91.1%  
Debtors Days Days7194 75.6%  
Net fixed assets Rs m8,333133,236 6.3%   
Share capital Rs m611,024 6.0%   
"Free" reserves Rs m3,443102,733 3.4%   
Net worth Rs m3,504103,757 3.4%   
Long term debt Rs m46132,146 1.4%   
Total assets Rs m13,755236,866 5.8%  
Interest coverage x1.55.4 27.2%   
Debt to equity ratio x0.10.3 42.5%  
Sales to assets ratio x0.30.6 55.2%   
Return on assets %10.66.5 162.3%  
Return on equity %11.711.6 100.6%  
Return on capital %38.713.7 281.9%  
Exports to sales %20.90-   
Imports to sales %8.10-   
Exports (fob) Rs m954NA-   
Imports (cif) Rs m372NA-   
Fx inflow Rs m1,20352,752 2.3%   
Fx outflow Rs m46714,504 3.2%   
Net fx Rs m73638,248 1.9%   
CASH FLOW
From Operations Rs m1,04925,054 4.2%  
From Investments Rs m-54-10,123 0.5%  
From Financial Activity Rs m-1,011-10,942 9.2%  
Net Cashflow Rs m-203,989 -0.5%  

Share Holding

Indian Promoters % 74.5 74.8 99.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 8.3 7.2%  
FIIs % 1.3 5.9 22.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 11.0 214.5%  
Shareholders   10,259 44,069 23.3%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Lower, Dow Futures Up by 18 Points(12:30 pm)

Share markets in India are presently trading marginally lower. The BSE Sensex is trading down by 17 points, flat at 48,064 levels.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Apr 23, 2021 01:59 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS